Quarterly Updates23 Jan 2026, 01:41 pm
Cipla Ltd Reports Q3FY26 Results: Double-digit Growth in India, Steady Performance in North America, Europe, and Emerging Markets
AI Summary
Cipla Ltd, a global pharmaceutical company, announced its unaudited consolidated financial results for the quarter ended December 31, 2025. The company reported a 10% YoY growth in its One-India business, with the North America business delivering a quarterly revenue of $167 Mn. The prescription business in South Africa maintained its No.2 position, while the business in Emerging Markets and Europe delivered a growth of 7% YoY in USD terms. The company's R&D investments stood at INR 494 Cr, accounting for 7.0% of sales.
Key Highlights
- One-India business grew at a solid 10% YoY
- North America business delivered a quarterly revenue of $167 Mn
- South Africa prescription business maintained its No.2 position
- Emerging Markets and Europe delivered a growth of 7% YoY in USD terms
- R&D investments stood at INR 494 Cr, accounting for 7.0% of sales